
Insuline glargine has several clinical and quality of life benefits compared with human basal insulin (NPH). However, it is also more costly. Do these benefits justify the additional cost? A new economic evaluation addresses this question. The authors searched the literature for published evaluations. They found seven good quality studies that addressed the issue, though [read the full story…]